Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2023 | Transcription factor FoxO1 mediates cell survival during BCR inhibitor therapy in CLL

Marek Mráz • 7 Oct 2023
iwCLL 2023
Chronic Lymphocytic Leukemia Leukemia BTK inhibitors Ibrutinib Idelalisib

In this interview, Marek Mráz, PhD, Central European Institute of Technology, Brno, Czech Republic, outlines a study on resistance of chronic lymphocytic leukemia (CLL) to BCR inhibitor therapy through increased activity of the FoxO1-Rictor-pAkt axis. This highlights the potential of FoxO1 as a novel therapeutic target, with testing of a FoxO1 inhibitor in vitro showing its ability to kill CLL cells.This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Marek Mráz

1:01
CLL resistance mechanisms in the era of novel agents
Marek Mráz • 7 Oct 2023
4:04
The impact of regulatory RNA molecules
Marek Mráz • 20 Sep 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals